This prospective study investigates whether measurement of plasma intestinal-fatty acid binding protein (I-FABP), a sensitive marker for small intestinal epithelial damage, improves non-invasive diagnosing of celiac disease (CD), and whether I-FABP levels are useful to evaluate mucosal healing in patients on a gluten-free diet (GFD). Ninety children with elevated tTG-IgA titres and HLA-DQ2/DQ8 positivity were included (study group). Duodenal biopsies were taken, except in those fulfilling the ESPGHAN criteria. Plasma I-FABP levels and tTG-IgA titres were assessed sequentially during six months of follow-up. Eighty children with normal tTG-IgA titres served as control group. In 61/90 (67.8%) of the children in the study group an increased I-FABP level was found; in all these children CD diagnosis was confirmed. Interestingly, in 14/30 (46.7%) children with slightly elevated tTG-IgA titres (<10x upper limit of normal), an increased I-FABP level was found. In all these children the diagnosis of CD was confirmed histologically. After gluten elimination for six weeks I-FABP levels had decreased towards levels in the control group. Measurement of plasma I-FABP, in addition to tTG-IgA, EMA-IgA and HLAtyping, enables non-invasive diagnosing of CD in a substantial number of children, and might therefore be of value in the diagnostic approach of CD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561259 | PMC |
| http://dx.doi.org/10.1038/s41598-017-07242-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Celiac Disease (CD)-related antibody positivity in children with Type 1 Diabetes (T1D) may fluctuate and become negative spontaneously. There are uncertainties about the optimal tTG-IgA titre and timing of endoscopy in the diagnosis of CD, and this study aimed to contribute to the debate on the tTGA-IgA threshold titre for endoscopy decisions in children with T1D.
Methods: The data of 991 children with T1D who had undergone serologic evaluation for CD were analysed retrospectively.
Prevalence of celiac disease in patients with type 1 diabetes mellitus: a single-center cross-sectional cohort study.
J Clin Biochem Nutr
November 2024
Department of Diabetes and Endocrinology, Hyogo Prefectural Harima-Himeji General Medical Center, 3-264, Kamiya-cho, Himeji-shi, Hyogo 670-8560, Japan.
Article Synopsis
- * The research included 115 T1DM patients and assessed their dietary habits, abdominal symptoms, and serum anti-tissue transglutaminase (TTG) antibody levels to diagnose CD.
- * Results showed that 50.4% of patients reported abdominal symptoms, but none had elevated TTG levels, leading to the conclusion that the prevalence of CD in Japanese patients with T1DM is 0%, indicating a lower occurrence than seen in other countries.
Tissue transglutaminase immunoglobulin A exceeds endomysial antibody in specificity of celiac diagnosis at ≥10 times the upper limit of normal.
J Pediatr Gastroenterol Nutr
December 2024
Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA.
Objective: Serologic diagnosis using tissue transglutaminase immunoglobulin A (TTG-IgA) and endomysial antibody (EMA) is being integrated into the care of pediatric patients with positive screening for celiac disease. The purpose of this study was to assess the utility of EMA in pediatric patients being considered for serologic diagnosis.
Methods: Patients with TTG-IgA testing performed between May 1, 2022 and April 30, 2023 and with subsequent duodenal biopsy within 6 months were included.
Exploring Total Immunoglobulin A's Impact on Non-Biopsy Diagnosis of Celiac Disease: Implications for Diagnostic Accuracy.
Nutrients
September 2024
Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Article Synopsis
- The study examines how total IgA levels affect the accuracy of non-invasive celiac disease (CeD) diagnoses using tTG-IgA thresholds.
- Results show that varying tTG-IgA cutoffs can significantly impact specificity and sensitivity, especially depending on the total IgA levels of patients.
- The findings suggest that clinicians should consider total IgA levels alongside traditional measures for more accurate CeD diagnoses.
Performance of deamidated gliadin peptide antibodies as first screening for celiac disease in the general pediatric population.
Front Pediatr
November 2023
Department of Medical Translational Sciences & European Laboratory for the Investigation of Food-Induced Diseases, University Federico II, Naples, Italy.
Background: Celiac serology has evolved, with the identification of newer antibodies against deamidated gliadin peptides (DGP) [e.g., anti-DGP, immunoglobulin A (IgA), and immunoglobulin G (IgG) types] with sensitivity and specificity in detecting celiac disease (CeD) that are equivalent to anti-tissue transglutaminase [anti-tissue transglutaminase (TTG) IgA]-based tests, particularly in populations with high pretest probability of CeD (prevalence of CeD > 50% of the population under study).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!